Newsroom Categories: Press release

  • McDermott advises LLCP-backed cleversoft Group on its Acquisition of tetralog systems

    McDermott advises LLCP-backed cleversoft Group on its Acquisition of tetralog systems

    DEAL ANNOUNCEMENT / PRESS RELEASE

    McDermott advises LLCP-backed cleversoft Group on its Acquisition of tetralog systems

    May 24, 2024

    Read time: 3 min

    Munich, May 24, 2024 – With a team led by Holger Ebersberger and Thomas Diekmann, McDermott Will & Emery represented Levine Leichtman Capital Partners-backed cleversoft Group on its acquisition of tetralog systems AG.

    The acquisition enhances cleversoft’s service portfolio with WealthTech solutions for portfolio analysis and optimization, supporting its broader expansion strategy.

    Founded in 2004 and headquartered in Munich, cleversoft is a leading provider of regulatory financial services technology. The group provides over 1,000 financial institutions worldwide with solutions to optimize business-relevant compliance processes.

    Tetralog systems AG has been digitizing the investment advisory process for financial institutions in Europe for more than 30 years. Its customers include renowned Tier 1 banks and asset managers. As part of cleversoft Group, tetralog systems will continue to operate in the market under its traditional name.

    Levine Leichtman Capital Partners (LLCP) acquired cleversoft from Main Capital in 2023. A team from McDermott Will & Emery also advised on this transaction.

    The McDermott team was led by Holger H. Ebersberger and Thomas Diekmann and included Marion Dalvai-König, Armin Teymouri, Steffen Woitz, Lukas Deutzmann, Claus Färber, Florian Schiefer and Christian Rolf.

    About Us
    You may also like

  • Schulte Roth & Zabel Secures Important Win for Activist Investors

    Schulte Roth & Zabel Secures Important Win for Activist Investors

    PRESS RELEASE

    Schulte Roth & Zabel Secures Important Win for Activist Investors

    May 23, 2024

    Read time: 6 min

    In a decision that has major implications for the shareholder activism space, the United States Court of Appeals for the Second Circuit became the first circuit court in the country to hold that an investor can moot a Section 13(d) claim related to missing or inadequate disclosures by disclosing the existence of the dispute itself, making it more difficult for incumbent management to use Section 13(d) as a weapon in proxy contests.

    On May 20, 2024, the Second Circuit affirmed the District Court’s dismissal of a Section 13(d) claim by Nano Dimension Ltd., an Israeli 3D printing company whose shares trade as NNDM on Nasdaq, against its two largest shareholders, Murchinson Ltd. and Anson Funds, Inc., and certain affiliates. 

    Nano Dimension Ltd. v. Murchinson Ltd., et al., in which Schulte Roth & Zabel presented argument on behalf of all Appellees, is part of a multi-front litigation between Nano and Murchinson that is the subject of multiple pending actions in the courts of Israel, US federal courts and New York state court.

    When activist investors that beneficially own more than five percent of a registered class of a public company’s voting equity securities seek to effect change at the company, Section 13(d) of the Securities and Exchange Act of 1934 requires them to make certain disclosures, including whether the investor has formed a “group” with other investors. The Supreme Court has made clear that, when enacting Section 13(d), “Congress expressly disclaimed an intention to provide a weapon for management to discourage takeover bids or prevent large accumulations of stock which would create the potential for such attempts.” (Rondeau v. Mosinee Paper Corp., 422 U.S. 49, 58 (1975)). 

    Nevertheless, all too often in proxy contests, companies abuse Section 13(d) by deploying it as a weapon and suing investors for purportedly failing to make adequate disclosures under Section 13(d). When doing so, companies often accuse activist investors of forming a “group” with other investors, and seek remedies such as share divestiture and share sterilization that would provide incumbent management with a decided advantage in corporate elections. In addition, by doing so, companies seek to change the narrative, obtain discovery from the activist and subject the activist to costly and time-consuming litigation.

    In keeping with Section 13(d)’s purpose, certain district courts, but no circuit court, have found that investors may moot such Section 13(d) claims by appending a copy of the complaint to an amended Schedule 13D filing and disputing the claims alleged. By doing so, the market is advised of the dispute, including the company’s allegations, and therefore the informational purposes of Section 13(d) have been served. However, no circuit court had ever adopted this rule.

    In January of 2023, Murchinson called a special meeting of Nano shareholders in Israel. Nano then sued Murchinson in Israeli court contesting its legal ability to call the special meeting. In advance of the special meeting, both Murchinson and Anson had been publicly critical of Nano’s incumbent management. Nano then sued Murchinson and Anson under Section 13(d) in the Southern District of New York, accusing them of being an undisclosed group and moving for a preliminary injunction in which Nano sought to void votes that Murchinson and Anson had already cast at the special meeting, and to enjoin them from purchasing or selling Nano shares. Murchinson and Anson disclosed the company’s allegations to shareholders by appending Nano’s complaint to their respective amended Schedule 13Ds and disputing the allegations.

    As the Second Circuit held on May 20, the amended Schedule 13Ds accomplished the informational purposes of Section 13(d) and the claim was thus moot: “The record here demonstrated a dispute as to whether Defendants acted as a group, and Nano presented no plausible basis in its complaint to reasonably infer that the dispute was not genuine or in good faith. Defendants’ amended filings disclosed the possibility of the disputed fact, and we agree with the district court that ‘Section 13(d) requires no more in this case.’” (Nano Dimension Ltd. v. Murchinson Ltd., et al., No. 23-1141 (2d Cir. May 20, 2024), Doc. 101-1 at 9.)

    With the Second Circuit’s decision, it will be significantly harder for incumbent management to abuse Section 13(d) and use it as a weapon in proxy contests against activist investors.  Activist investors now have a simple way to moot a Section 13(d) disclosure claim that they dispute in good faith. This removal of an arrow in incumbent management’s quiver will make proxy contests more efficient and less expensive, and encourage proxy fights to play out in the market where they belong, rather than in the courtroom.

    The Schulte litigation team was led by Michael Swartz, co-chair of the firm’s Litigation Group and included partner Randall Adams, special counsel Mark Garibyan and associates Erika Simonson, Sedinam Anyidoho and Joe Pisicolo. The team was assisted by Ele Klein, co-chair of the firm’s M&A and Securities Group and co-chair of the firm’s Global Shareholder Activism Group, partner Adriana Schwartz and special counsel Brandon Gold.

    About Us

    Joseph A. Pisicolo

    Associate

    New York – 919 Third Avenue

    Ele Klein

    Partner

    New York – 919 Third Avenue

    Brandon S. Gold

    Partner

    New York – 919 Third Avenue

    You may also like

  • McDermott Partners Doug Carsten and Bill Gaede Named Among Top Intellectual Property Lawyers by Daily Journal

    AWARDS & RANKINGS / PRESS RELEASE

    McDermott Partners Doug Carsten and Bill Gaede Named Among Top Intellectual Property Lawyers by Daily Journal

    May 22, 2024

    Read time: 3 min

    May 22, 2024 – International law firm McDermott Will & Emery is pleased to announce that Doug Carsten and Bill Gaede have been named to the Daily Journal’s 2024 Top Intellectual Property Lawyers list.

    Bill is the head of McDermott’s global Intellectual Property Practice Group and focuses his practice on intellectual property litigation in the life sciences and medical device industries. He serves as lead counsel for a wide range of companies and research institutes and has extensive experience in litigating life sciences technologies such as antibodies, proteins, small molecules and diagnostics. In addition to his jury trial experience, Bill has argued before the US Circuit Court of Appeals for the Federal Circuit.

    Doug focuses his practice on complex patent litigation disputes. He counsels clients in various technology areas, including pharmaceuticals, biologics, medical devices, diagnostic products, retail products and computer software. He has substantial first-chair trial experience that includes litigating high-profile and billion-dollar patent cases. Doug also serves as co-head of the Firm’s global life sciences practice.

    The Daily Journal’s Top Intellectual Property Lawyers list recognizes standout lawyers in California based on career accomplishments and major achievements in the area of intellectual property over the past year.

    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    Douglas H. Carsten

    Partner

    San Diego

    William Gaede

    Partner

    Silicon Valley, San Francisco

    You may also like

  • McDermott Advises Verdoso on its Strategic Investment in Estelec Industrie

    McDermott Advises Verdoso on its Strategic Investment in Estelec Industrie

    DEAL ANNOUNCEMENT / PRESS RELEASE

    McDermott Advises Verdoso on its Strategic Investment in Estelec Industrie

    May 22, 2024

    Read time: 3 min

    McDermott Will & Emery has advised Verdoso, an investment holding specializing in assisting small and medium-sized businesses in their transformation phases, on a strategic investment in Estelec Industrie, a fast-growing Alsatian electronics company (EMS).

    Thanks to this partnership with Verdoso, the company will be able to strengthen its financial base and production capacities, expand its presence in new markets and continue to offer its customers cutting-edge technological solutions.

    The investment aims to position Estelec Industrie as a leading French EMS.

    A member of the BPI Gas Pedal and DGE ETIncelles programs, and a FrenchFab ambassador, Estelec Industrie relies on 100% French production through two production sites in Alsace, both at the cutting edge of the latest technologies.

    The McDermott team that advised Verdoso was composed of :

    • Fabrice Piollet – Partner
    • Julien-Pierre Tannoury and Fayçal Laraki – associates
    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    You may also like

  • McDermott advises MaaT Pharma on its EUR19.2 Million Global Offering

    McDermott advises MaaT Pharma on its EUR19.2 Million Global Offering

    DEAL ANNOUNCEMENT / PRESS RELEASE

    McDermott advises MaaT Pharma on its EUR19.2 Million Global Offering

    May 21, 2024

    Read time: 3 min

    McDermott Will & Emery has advised MaaT Pharma, a late-stage biotechnology company leading the development of Microbiome Ecosystem TherapiesTM to improve the survival of cancer patients, on its EUR19.2 million offering, comprising a reserved offering of new ordinary shares to institutional investors and a public offering of new ordinary shares via the PrimaryBid platform, as well as a secondary offering of existing ordinary shares held by certain funds managed by Seventure Partners, at a price of EUR8 per share.

    The McDermott team advising Maat Pharma included partners Bertrand Delafaye and Emmanuelle Trombe and associates Henri Nalbandyan and Amel El Mouttaki.

    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    You may also like

  • McDermott Adds Senior Restructuring Lawyer in London

    PRESS RELEASE

    McDermott Adds Senior Restructuring Lawyer in London

    May 20, 2024

    Read time: 3 min

    International law firm McDermott Will & Emery welcomes Adrian Cohen as a senior consultant in its transactions practice in London. Adrian will support the Firm’s established team in advising clients on their most complex cross-border restructurings and special situations.

    “We’re excited to welcome Adrian to our vibrant team,” said Mark Fennessy, co-head of the London Transactions Group. “His primary focus will be on restructuring and insolvency, both transactional and advisory, for a variety of corporates and financial stakeholders with a particular interest in multi-jurisdictional situations. We look forward to drawing on his significant experience.”

    Bringing more than three decades of experience, Adrian’s background spans multiple sectors, including real estate, hotels and leisure, media and entertainment, aircraft finance, infrastructure and project finance, energy, mining and steel production, financial services and banking. He regularly advises on cross-border mandates, particularly in matters related to continental Europe and emerging markets such as the Gulf and Eastern Europe. Adrian has worked for lenders, agents, security agents, sponsors and corporate borrowers, commercial counterparties, derivative counterparties, and governmental and regulatory agencies.”

    “Adrian’s appointment is yet another step in our accelerated growth in London,” added Aymen Mahmoud, co-head of the London Transactions Group and incoming London office managing partner. “As we’re enhancing our transactional footprint with the recent hires of Michal Berkner, Graham White and Fatema Orjela, we’re also boosting our restructuring capabilities to continue helping businesses in this challenging, fast-moving market.”

    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    Mark Fennessy

    Partner

    London – 22 Bishopsgate

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    You may also like

  • McDermott Advises ODDO BHF AM on the Final Closing of Secondaries Fund II

    McDermott Advises ODDO BHF AM on the Final Closing of Secondaries Fund II

    DEAL ANNOUNCEMENT / PRESS RELEASE

    McDermott Advises ODDO BHF AM on the Final Closing of Secondaries Fund II

    May 17, 2024

    Read time: 3 min

    McDermott Will & Emery advised ODDO BHF AM on the final closing of its second secondary fund ODDO BHF Secondaries Fund II at EUR715 million.

    This closing exceeded the initial target of EUR500 million.

    With this second vintage, ODDO BHF AM is pursuing its strategy of addressing all types of secondary transactions worldwide (including continuation-GP led funds), with a particular focus on mid- and large-cap assets.

    The McDermott team that advised ODDO BHF AM comprised:

    • Guillaume Panuel, partner, Agathe Marcelin and Clémence Naudin, associates
    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    Guillaume Panuel

    Partner

    Paris

    Agathe Marcelin

    Associate

    Paris

    Clémence Naudin

    Associate

    Paris

    You may also like

  • McDermott Adds Investment Funds and Blockchain Veteran in California

    PRESS RELEASE

    McDermott Adds Investment Funds and Blockchain Veteran in California

    May 17, 2024

    Read time: 4 min

    International law firm McDermott Will & Emery welcomes Timothy (Tim) Spangler to its Transactions Practice Group as a partner in the Orange County and Silicon Valley offices. Joining from Dechert, Tim represents global clients at the intersection of investment management and disruptive financial technologies.

    “Investment firms are increasingly seeking to implement groundbreaking innovations to diversify their portfolios in today’s rapidly evolving global economy,” said Harris Siskind, global head of McDermott’s Transactions Practice Group. “Tim is a first-rate, innovative strategist who can see around corners to help clients with their most important business decisions.”

    Tim advises clients on the formation, structuring and negotiation of private investment vehicles and on the impact of digital assets on the financial services industry. He regularly works with fund sponsors and promoters, offering strategic advice on hedge, private equity and venture capital fund structuring and launches, including co-investment arrangements, internal partnerships and personal investments.

    He also counsels clients on a variety of US, UK and cross-border regulatory matters, including the Investment Advisers Act of 1940, the Financial Services and Markets Act 2000, the Alternative Investment Fund Managers Directive and the ever-evolving regulatory landscape.

    Some of Tim’s most notable work includes:

    • Advising Franklin Templeton on its launch of the first blockchain-based mutual fund in the United States
    • Representing Figure Technologies, Inc. in the launch of its Provenance blockchain, purpose-built for financial instruments and real-world assets
    • Representing several alternative fund managers in the launches of their private equity and hedge funds, including both onshore and offshore structures
    • Advising Fabric, a wealth technology platform specializing in portfolio design, customization, and analytics for wealth managers and advisors, on its acquisition by MSCI Inc., a leading provider of mission-critical decision support tools and services for the global investment community

    “McDermott’s year-over-year growth is incredibly impressive, and I’m thrilled at the opportunity to expand the Firm’s West Coast footprint,” Tim said. “The Firm already boasts exceptional talent in the funds formation space as well as market-leading experience in cryptocurrency insolvencies and disputes, and I’m eager to advise on the complex regulatory aspects of these transactions.”

    McDermott is committed to growing its transactions practice globally. Tim follows the recent arrivals of Jeeseon Ahn (Energy & Project Finance, New York), Michal Berkner (M&A, London), Julia Boyd (Private Equity, New York), Jonathan Ching (Financial Institutions, New York), Alexei Cowett (Venture Capital, New York), David Herman (Real Estate, New York), Howard Kleinman (Latin American M&A, New York), Andrew Kummer (Financial Institutions, New York), Fatema Orjela (Corporate Advisory, London), Kate Vera (Private Equity, New York), Matthias Weissinger (Finance, Munich) and Graham White (Private Equity, London).

    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    McDermott’s Transactions Practice Group represents business interests around the world, from global corporations and industry-leading companies to privately funded and entrepreneurial-driven enterprises, as well as the financial institutions that support them. The Firm consistently ranks in the leading league tables, including Mergermarket, Thomson Reuters, Bloomberg and PitchBook.

    Alexei Cowett

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Howard Kleinman

    Partner

    New York – One Vanderbilt Avenue

    Fatema Orjela

    Partner

    London – 22 Bishopsgate

    Graham White

    Senior Partner

    London – 22 Bishopsgate

    You may also like

  • McDermott Advises Chequers Capital on the Sale of its Stake in Fime to Gallant Capital

    McDermott Advises Chequers Capital on the Sale of its Stake in Fime to Gallant Capital

    DEAL ANNOUNCEMENT / PRESS RELEASE

    McDermott Advises Chequers Capital on the Sale of its Stake in Fime to Gallant Capital

    May 17, 2024

    Read time: 3 min

    McDermott Will & Emery has advised pan-European investment firm Chequers Capital on the sale of its stake in Fime, a global leader in testing and certification services in the fields of payments, smart mobility and digital identity, to Gallant Capital.

    The McDermott team advising Chequers Capital included :

    • Grégoire Andrieux, Partner, Stanislas Offroy, Associate, Robin Lamour, Robin, Associate, on the corporate aspects of the transaction
    • Abdel Abdellah, Associate, on employment law
    • Frédéric Pradelles, Partner, Mary Hecht, Associate, on competition law
    • Sabine Nauges, Partner on regulatory aspects
    • Côme de Saint-Vincent, Counsel, on tax law
    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    You may also like

  • McDermott Named Licensing & Collaboration Firm of the Year as Part of the LMG Life Sciences Awards EMEA 2024

    McDermott Named Licensing & Collaboration Firm of the Year as Part of the LMG Life Sciences Awards EMEA 2024

    AWARDS & RANKINGS / PRESS RELEASE

    McDermott Named Licensing & Collaboration Firm of the Year as Part of the LMG Life Sciences Awards EMEA 2024

    March 17, 2024

    Read time: 3 min

    May 17, 2024 – International law firm McDermott Will & Emery has been named Licensing & Collaboration Firm of the Year as part of the LMG Life Sciences Awards EMEA 2024 while Emmanuelle Trombe was named Licensing & Collaboration Lawyer of the Year.

    McDermott’s licensing and collaboration agreements team leverages the combined power of teamwork and industry understanding to provide in-depth guidance to clients in every sector of the life sciences space, integrating the knowledge and experience of lawyers from across the Firm’s many Tier 1 practices to meet specific individual needs.

    Emmanuelle is the co-head of the Firm’s Life Sciences Group and serves as an elected member of the Firm’s Management Committee. She represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters related to mergers and acquisitions (M&A) and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters.

    Additionally, McDermott and two of its lawyers were shortlisted in the following categories:

    • M&A Firm of the Year
    • Venture Capital Firm of the Year
    • France Firm of the Year
    • Corporate Rising Star – Anne-France Moreau
    • Financial Rising Star – Lucie Martin

    The LMG Life Sciences Awards EMEA aim to honor firms and lawyers at the forefront of legal work in life sciences. The awards’ distinctive structure highlights firms and lawyers that specialize in practice areas within the life sciences industry by shortlisting firms and by listing nominees in a way that shows overlap between certain legal areas.

    View the full list of winners.

    About Us

    McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

    You may also like